Journal Mobile Options
Table of Contents
Vol. 23, No. 3, 2010
Issue release date: March 2010
Section title: Original Paper
Free Access
Skin Pharmacol Physiol 2010;23:139–151

Identification of Novel in vitro Test Systems for the Determination of Glucocorticoid Receptor Ligand-Induced Skin Atrophy

Schoepe S.a, b · Schäcke H.a · Bernd A.c · Zöller N.c · Asadullah K.b, d
aCommon Mechanism Research Berlin and bTarget Discovery, Global Drug Discovery, Bayer Schering Pharma AG, Berlin, and cDepartment of Dermatology and Venerology, J.W. Goethe University, Frankfurt/Main, and dGerman Skin Research Center, Berlin, Germany
email Corresponding Author

Prof. Dr. med. Khusru Asadullah

Target Discovery, Bayer Schering Pharma AG

DE–13342 Berlin (Germany)

Tel. +49 30 468 14853, Fax +49 30 468 192 374



  1. Sterry W, Asadullah K: Topical glucocorticoid therapy in dermatology. Ernst Schering Res Found Workshop 2002;40:39–54.
  2. Niedner R: Glukokortikosteroide in der Dermatologie: Kontrollierter Einsatz erforderlich. Dtsch Ärztebl 1996;93:A2868–A2872.
  3. Luger T, Loske KD, Elsner P, Kapp A, Kerscher M, Korting HC, Krutmann J, Nickner R, Röcken M, Ruzicka T, Schwarz T: Topische Dermatotherapie mit Glukokortikoiden – Therapeutischer Index. J Dtsch Dermatol Ges 2004;2:629–634.
  4. Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J, Nietsch KH: Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol 2002;15:85–91.
  5. Kimura T, Doi K: Dorsal skin reactions of hairless dogs to topical treatment with corticosteroids. Toxicol Pathol 1999;27:528–535.
  6. Booth BA, Tan EM, Oikarinen A, Uitto J: Steroid-induced dermal atrophy: effects of glucocorticosteroids on collagen metabolism in human skin fibroblast cultures. Int J Dermatol 1982;21:333–337.
  7. Mills CM, Marks R: Side effects of topical glucocorticoids. Curr Probl Dermatol 1993;21:122–131.
  8. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T: Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 2001;7:73–77.
  9. Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, Ahn SK, Brown BE, Elias PM, Feingold KR: Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003;120:456–464.
  10. Sheu HM, Yu HS, Sheen TC: Histochemical and ultrastructural studies on cutaneous side effects due to topical corticosteroids. 1. Changes in epidermis. Derm Sinica 1989;7:143–153.
  11. Saarni H, Hopsu-Havu VK: The decrease of hyaluronate synthesis by anti-inflammatory steroids in vitro. Br J Dermatol 1978;98:445–449.
  12. Lehmann P, Zheng P, Lavker RM, Kligman AM: Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J Invest Dermatol 1983;81:169–176.
  13. Cutroneo KR, Rokowski R, Counts DF: Glucocorticoids and collagen synthesis: comparison of in vivo and cell culture studies. Coll Relat Res 1981;1:557–568.
  14. Nuutinen P, Autio P, Hurskainen T, Oikarinen A: Glucocorticoid action on skin collagen: overview on clinical significance and consequences. J Eur Acad Dermatol Venereol 2001;15:361–362.
  15. Schoepe S, Schäcke H, May E, Asadullah K: Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006;15:406–420.
  16. Schäcke H, Docke WD, Asadullah K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23–43.
  17. Mirshahpanah P, Döcke WD, Merbold U, Asadullah K, Röse L, Schäcke H, Zollner TM: Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. Exp Dermatol 2007;16:753–761.
  18. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K: Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004;101:227–232.
  19. Wach F, Bosserhoff A, Kurzidym U, Nowok K, Landthaler M, Hein R: Effects of mometasone furoate on human keratinocytes and fibroblasts in vitro. Skin Pharmacol Appl Skin Physiol 1998;11:43–51.
  20. Ponec M, De Haas C, Bachra BN, Polano MK: Effects of glucocorticosteroids on cultured human skin fibroblasts. 3. Transient inhibition of cell proliferation in the early growth stages and reduced susceptibility in later growth stages. Arch Dermatol Res 1979;265:219–227.
  21. Schäcke H, Berger M, Rehwinkel H, Asadullah K: Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007;275:109–117.
  22. Kurzen H, Henrich C, Booken D, Poenitz N, Gratchev A, Klemke CD, Engstner M, Goerdt S, Maas-Szabowski N: Functional characterization of the epidermal cholinergic system in vitro. J Invest Dermatol 2006;126:2458–2472.
  23. Mewes KR, Raus M, Bernd A, Zöller NN, Sattler A, Graf R: Elastin expression in a newly developed full-thickness skin equivalent. Skin Pharmacol Physiol 2007;20:85–95.
  24. Schottelius AJ, Zugel U, Docke WD, Zollner TM, Rose L, Mengel A, Buchmann B, Becker A, Grutz G, Naundorf S, Friedrich A, Gaestel M, Asadullah K: The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-alpha pathway of systemic and cutaneous inflammation. J Invest Dermatol 2009, E-pub ahead of print.
  25. Li YY, Bao M, Meurer J, Skuballa W, Bauman JG, Doecke WD, Zollner TM: The identification of a small molecule inhibitor that specifically reduces T cell-mediated adaptive but not LPS-mediated innate immunity by T cell membrane-monocyte contact bioassay. Immunol Lett 2008;117:114–118.
  26. Zöller NN, Kippenberger S, Thaci D, Mewes K, Spiegel M, Sattler A, Schultz M, Bereiter-Hahn J, Kaufmann R, Bernd A: Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model. Toxicol In Vitro 2008;22:747–759.
  27. Zerbe GO: On Fieller’s theorem and the general linear model. The Am Stat 1978;32:103–105.
    External Resources
  28. Dixon WJ: Processing data for outliers. Biometrics 1953;9:74–89.
    External Resources
  29. Wiedersberg S, Leopold CS, Guy RH: Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm 2008;68:453–466.
  30. Commandeur S, de Gruijl FR, Willemze R, Tensen CP, El Ghalbzouri A: An in vitro three-dimensional model of primary human cutaneous squamous cell carcinoma. Exp Dermatol 2009;18:849–856.